By Dean Seal
General Electric Co.'s healthcare business and Lantheus Holdings Inc. said Tuesday that the Phase 3 clinical trial for their investigational radiotracer met co-primary endpoints in the detection of coronary artery disease.
The companies said the trial for the radiotracer, dubbed [18F]flurpiridaz, met the co-primary endpoints of exceeding a 60% threshold for both sensitivity and specificity for detecting heart disease.
The trial also met its first key secondary endpoint by demonstrating that [18F]flurpiridaz Positron Emission Tomography has higher diagnostic efficacy for patients with suspected coronary artery disease when compared with the predominant procedure used in nuclear cardiology today.
GE Healthcare has led the funding and development of the investigational agent and will have global commercialization rights to the imaging agent if it is approved. Lantheus has collaborated on the development and will work with GE on a potential commercialization through a joint steering committee, with entitlement to royalties based on commercial sales.
Write to Dean Seal at firstname.lastname@example.org
(END) Dow Jones Newswires